BACKGROUND: Altered regulation of many transcription factors has been shown to be important in the development of leukemia. TWIST2 modulates the activity of a number of important transcription factors and is known to be a regulator of hematopoietic differentiation. Here, we investigated the significance of epigenetic regulation of TWIST2 in the control of cell growth and survival and in response to cytotoxic agents in acute lymphoblastic leukemia. DESIGN AND METHODS: TWIST2 promoter methylation status was assessed quantitatively, by combined bisulfite and restriction analysis (COBRA) and pyrosequencing assays, in multiple types of leukemia and TWIST2 expression was determined by quantitative reverse transcriptase polymerase chain reaction analysis. The functional role of TWIST2 in cell proliferation, survival and response to chemotherapy was assessed in transient and stable expression systems. RESULTS: We found that TWIST2 was inactivated in more than 50% of cases of childhood and adult acute lymphoblastic leukemia through promoter hypermethylation and that this epigenetic regulation was especially prevalent in RUNX1-ETV6-driven cases. Re-expression of TWIST2 in cell lines resulted in a dramatic reduction in cell growth and induction of apoptosis in the Reh cell line. Furthermore, re-expression of TWIST2 resulted in increased sensitivity to the chemotherapeutic agents etoposide, daunorubicin and dexamethasone and TWIST2 hypermethylation was almost invariably found in relapsed adult acute lymphoblastic leukemia (91% of samples hypermethylated). CONCLUSIONS: This study suggests a dual role for epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia, initially through altering cell growth and survival properties and subsequently by increasing resistance to chemotherapy.
BACKGROUND: Altered regulation of many transcription factors has been shown to be important in the development of leukemia. TWIST2 modulates the activity of a number of important transcription factors and is known to be a regulator of hematopoietic differentiation. Here, we investigated the significance of epigenetic regulation of TWIST2 in the control of cell growth and survival and in response to cytotoxic agents in acute lymphoblastic leukemia. DESIGN AND METHODS: TWIST2 promoter methylation status was assessed quantitatively, by combined bisulfite and restriction analysis (COBRA) and pyrosequencing assays, in multiple types of leukemia and TWIST2 expression was determined by quantitative reverse transcriptase polymerase chain reaction analysis. The functional role of TWIST2 in cell proliferation, survival and response to chemotherapy was assessed in transient and stable expression systems. RESULTS: We found that TWIST2 was inactivated in more than 50% of cases of childhood and adult acute lymphoblastic leukemia through promoter hypermethylation and that this epigenetic regulation was especially prevalent in RUNX1-ETV6-driven cases. Re-expression of TWIST2 in cell lines resulted in a dramatic reduction in cell growth and induction of apoptosis in the Reh cell line. Furthermore, re-expression of TWIST2 resulted in increased sensitivity to the chemotherapeutic agents etoposide, daunorubicin and dexamethasone and TWIST2 hypermethylation was almost invariably found in relapsed adult acute lymphoblastic leukemia (91% of samples hypermethylated). CONCLUSIONS: This study suggests a dual role for epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia, initially through altering cell growth and survival properties and subsequently by increasing resistance to chemotherapy.
Authors: Aparna Raval; David M Lucas; Jennifer J Matkovic; Kristi L Bennett; Sandya Liyanarachchi; Donn C Young; Laura Rassenti; Thomas J Kipps; Michael R Grever; John C Byrd; Christoph Plass Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Yun Sok Lee; Hyoung Ho Lee; Jiyoung Park; Eung Jae Yoo; Carlotta A Glackin; Young Il Choi; Sung Ho Jeon; Rho Hyun Seong; Sang Dai Park; Jae Bum Kim Journal: Nucleic Acids Res Date: 2003-12-15 Impact factor: 16.971
Authors: Gordon Strathdee; Tessa L Holyoake; Alyson Sim; Anton Parker; David G Oscier; Junia V Melo; Stefan Meyer; Tim Eden; Anne M Dickinson; Joanne C Mountford; Heather G Jorgensen; Richard Soutar; Robert Brown Journal: Clin Cancer Res Date: 2007-09-01 Impact factor: 12.531
Authors: Andrew B Sharabi; Melissa Aldrich; Drazen Sosic; Eric N Olson; Alan D Friedman; Sung-Hyung Lee; Si-Yi Chen Journal: PLoS Biol Date: 2008-12-16 Impact factor: 8.029
Authors: Hye-Jung E Chun; Emilia L Lim; Alireza Heravi-Moussavi; Saeed Saberi; Karen L Mungall; Mikhail Bilenky; Annaick Carles; Kane Tse; Inna Shlafman; Kelsey Zhu; Jenny Q Qian; Diana L Palmquist; An He; William Long; Rodrigo Goya; Michelle Ng; Veronique G LeBlanc; Erin Pleasance; Nina Thiessen; Tina Wong; Eric Chuah; Yong-Jun Zhao; Jacquie E Schein; Daniela S Gerhard; Michael D Taylor; Andrew J Mungall; Richard A Moore; Yussanne Ma; Steven J M Jones; Elizabeth J Perlman; Martin Hirst; Marco A Marra Journal: Cancer Cell Date: 2016-03-14 Impact factor: 31.743
Authors: X Zhang; W Ma; J Cui; H Yao; H Zhou; Y Ge; L Xiao; X Hu; B-H Liu; J Yang; Y-Y Li; S Chen; C J Eaves; D Wu; Y Zhao Journal: Oncogene Date: 2014-08-04 Impact factor: 9.867
Authors: Yue Guo; Jong Hun Lee; Limin Shu; Ying Huang; Wenji Li; Chengyue Zhang; Anne Yuqing Yang; Sarandeep Ss Boyanapalli; Ansu Perekatt; Ronald P Hart; Michael Verzi; Ah-Ng Tony Kong Journal: Cell Biosci Date: 2015-05-27 Impact factor: 7.133
Authors: Shinji Maegawa; Sheryl M Gough; Naoko Watanabe-Okochi; Yue Lu; Nianxiang Zhang; Ryan J Castoro; Marcos R H Estecio; Jaroslav Jelinek; Shoudan Liang; Toshio Kitamura; Peter D Aplan; Jean-Pierre J Issa Journal: Genome Res Date: 2014-01-10 Impact factor: 9.043